Aryl piperazine modified benzo [b] thiophene compound, and its preparing method and use

Abstract

The invention discloses aryl piperazine attributive benzo[b] thiophene compound with antidepressant activity structure and its preparing method and the application. Its preparing method includes the following steps: adding 1mol 3-propionyl benzo[b] thiophene, 1-5mol paraformaldehyde, and 1-5mol aryl piperazine hydrochloride into the alcohol with 1-50 times weight ratio; reacting for 1-80h at back flow to generate 1-(benzo[b]thiophene-3-group)-2-methyl-3-(4-aryl piperazine-1-group)-1-acetone; adding 1mol the above generated compound and 0.2-5mol sodium borohydride into the alcohol with 1-50 times weight ratio; reacting for 1-20h at 0-100 degree centigrade to generate 1-(benzo[b] thiophene -3-group)-2-methyl-3-(4-aryl piperazine-1-group) -1-propanol. This compound can be used in antidepressant preparing by itself free alkali or salt form. The invention has the advantages of simple preparing process and easy operation.

Description

technical field [0001] The invention relates to the structure, preparation method and application of an arylpiperazine-modified benzo[b]thiophene compound with antidepressant activity, and belongs to the field of medicinal chemistry. Background technique [0002] Depression is a common mental illness, which is an emotional disorder. As the pace of life continues to accelerate, people's mental pressure is gradually increasing. Depression has become a common disease in modern society, with a high incidence, and its incidence is rising rapidly. : According to incomplete statistics, at present the world's depression patients have accounted for 3%-5% of the world's population, almost seen in all ages, and its prevalence is about 3% in the general population, and the patient population in general hospital health services In patients with chronic physical diseases (such as cardiovascular disease, diabetes), the rate of depressive disorder can be as high as 20%, but only a very smal...

AI Technical Summary

Problems solved by technology

[0003] Tricyclic antidepressants (TCA, Anticholinergic) appeared in the 1950s, and 5-HT selective reuptake inhibitors SSRIs (Fluoxetine, Paroxetine, Sertaline, Citalopram, Fluvoxamine) appeared in the 1980s because of their good antidepressant properties, It has gradually replaced TCA and has become the leading product in the antidepressant market. However, because SSRI indirectly acts on all 5-HT receptors, it has side effects such as nausea, anxiety, insomnia, and sexual dysfunction. The weakness is the hysteresis effect, that is, the antidepressant effect usually appears after the first 2-6 weeks after starting to take the medicine. Therefore, in order to find antidepressants that are safe, fast-acting, and have few side effects, pharmacists have conducted various researches. try

[0004] Since the 1990s, some antidepressants with new mechanisms of action have appeared, such as NE / 5-HT reuptake inhibitor SNRI (Venlaxine, Milnacipran, Duloxetine, Nefazodone), selective monoamine oxidase inhibitor MAOI (Moclobemide, Toloxatone), selective NE reuptake inhibitor Uptake inhibitor NARI (Reboxetine), NE energy and specific 5-HT energy antidepressant NaSSa (Mirtazapine). Although these drugs have improved efficacy and rapid onset compared with SSRIs, they still have 1- 2-week lag period, so research on faster-acting drugs is urgent

Images